Johnson & Johnson (NYSE:JNJ) Stock Has Average Price Target of $275.92 According to Analysts

Shares of Johnson & Johnson (NYSE:JNJ) have earned an average recommendation of “Moderate Buy” from the twenty-six research firms that are currently covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $275.92.

JNJ has been the topic of several analyst reports. Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. TD Cowen reissued a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 20th. Sanford C. Bernstein set a $270.00 price objective on shares of Johnson & Johnson in a research report on Thursday, October 15th. Scotiabank restated an “outperform” rating and set a $305.00 target price on shares of Johnson & Johnson in a research note on Thursday, July 16th. Finally, Evercore set a $300.00 target price on Johnson & Johnson in a report on Tuesday, October 20th.

Johnson & Johnson Trading Up 1.0%

JNJ opened at $266.38 on Friday. The stock has a market capitalization of $641.25 billion, a price-to-earnings ratio of 40.36, a P/E/G ratio of 2.61 and a beta of 0.21. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a twelve month low of $184.66 and a twelve month high of $281.07. The company has a 50-day simple moving average of $265.35 and a 200 day simple moving average of $245.32.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period in the prior year, the company posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Analysts predict that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson’s payout ratio is 81.21%.

Insider Buying and Selling

In related news, EVP Jennifer Taubert sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 64,515 shares of company stock worth $17,271,766 in the last ninety days. 0.16% of the stock is owned by insiders.

Institutional Investors Weigh In On Johnson & Johnson

A number of hedge funds have recently made changes to their positions in the stock. SYM FINANCIAL Corp raised its holdings in Johnson & Johnson by 2.6% in the 3rd quarter. SYM FINANCIAL Corp now owns 9,006 shares of the company’s stock valued at $2,384,000 after buying an additional 230 shares during the last quarter. Oakworth Capital Inc. boosted its position in Johnson & Johnson by 0.5% during the 3rd quarter. Oakworth Capital Inc. now owns 18,510 shares of the company’s stock worth $4,900,000 after buying an additional 93 shares during the period. MBE Wealth Management LLC grew its holdings in Johnson & Johnson by 12.3% during the 3rd quarter. MBE Wealth Management LLC now owns 1,958 shares of the company’s stock worth $518,000 after acquiring an additional 214 shares during the last quarter. Black Diamond Financial LLC grew its holdings in Johnson & Johnson by 22.6% during the 3rd quarter. Black Diamond Financial LLC now owns 2,907 shares of the company’s stock worth $770,000 after acquiring an additional 535 shares during the last quarter. Finally, Total Clarity Wealth Management Inc. increased its position in Johnson & Johnson by 16.2% in the 3rd quarter. Total Clarity Wealth Management Inc. now owns 6,621 shares of the company’s stock valued at $1,753,000 after acquiring an additional 922 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Promising prostate-cancer data: Experimental drug JNJ-6143 produced tumor-response rates of roughly 69% to 75% in heavily pretreated patients with advanced prostate cancer. The results support further development of the first-in-class RIPTAC drug, although the evidence remains early-stage. What Do Johnson & Johnson Cancer Trial Wins Mean For Its Stock?
• Positive Sentiment: RYBREVANT expansion potential: A subcutaneous RYBREVANT FASPRO combination generated a 77% overall response rate in first-line treatment of advanced head and neck cancer. The findings support the ongoing Phase 3 OrigAMI-5 trial and could broaden the commercial opportunity for a key oncology franchise. RYBREVANT FASPRO Head and Neck Cancer Results
• Positive Sentiment: ERLEADA showed a meaningful benefit: Johnson & Johnson said using ERLEADA before and after surgery reduced the risk of recurrence or death by 62% versus surgery alone in high-risk localized or locally advanced prostate cancer, potentially supporting broader adoption. ERLEADA Surgical Study Results
• Neutral Sentiment: ETF activity showed net selling of JNJ, but this is generally a short-term trading signal rather than a change in the company’s fundamentals.
• Negative Sentiment: An expected orthopedics merger with Smith & Nephew collapsed over leadership disagreements, removing a potential strategic opportunity. The strong cancer data also comes with clinical and regulatory risks because several programs remain in relatively early development.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.